Literature DB >> 24761653

[Pharmacokinetics and brain distribution of ginsenosides after administration of sailuotong].

Ying Zhang, Li Lin, Guang-Yu Liu, Jian-Xun Liu, Tao Li.   

Abstract

Sailuotong (SLT) is a compound preparation composed of ginseng, ginkgo and saffron for the treatment of vascular dementia In order to identify its material foundation and provide evidence for therapeutic regimen, the pharmacokinetics and brain distribution of ginsenosides were investigated after intragastric administration of SLT. An LC-MS/MS method was developed for the determination of 7 ginsenosides in rat plasma simultaneously. Statistical analysis of obtained data demonstrated that the method has achieved the desired linearity, precision, accuracy and sensitivity. After administration of SLT at 60 mg x kg(-1) dose, 7 ginsengosides were all absorbed into systematic circulation. The quantitative and statistical analysis of gensenosides in plasma showed that protopanaxdiol saponins exhibited higher concentration and longer half life than protopanaxatriol saponins. The mean value of half life of ginsenosides Rg1, Re, Rb1, Rb2/b3, Rc and Rd were 15.26, 2.46, 18.41, 27.70, 21.86 and 61.58 h respectively. The peak concentration of them were 7.15, 2.83, 55.32, 30.22, 21.42, 8.81 microg x L(-1) respectively. The determination of brain distribution at different time after dosing revealed ginsenosides entered into brain promptly but the concentration declined along with time rapidly. The ginsenosides with higher concentration in brain were Rg1, Re, Rb1 and Rc. These findings demonstrated ginsenosides could be absorbed in blood and penetrated into brain rapidly. Some ginsenosides, especially Rg1 and Re, might be the main components directly effecting neurocyte in brain taking advantage of their better brain distribution. While ginsenosides of mostly protopanaxdiol saponins might protect brain mainly depending on peripheral efficacy in virtue of their long residence in blood, by which higher concentration could be reached after multiple dosing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24761653

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  7 in total

1.  Endothelium-Independent Vasodilatory Effect of Sailuotong (SLT) on Rat Isolated Tail Artery.

Authors:  S Y Yeon; S W Seto; G H H Chan; M Low; H Kiat; N Wang; J Liu; D Chang
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-22       Impact factor: 2.629

Review 2.  Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases.

Authors:  Alexander G Panossian; Thomas Efferth; Alexander N Shikov; Olga N Pozharitskaya; Kenny Kuchta; Pulok K Mukherjee; Subhadip Banerjee; Michael Heinrich; Wanying Wu; De-An Guo; Hildebert Wagner
Journal:  Med Res Rev       Date:  2020-10-25       Impact factor: 12.944

Review 3.  A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease.

Authors:  Liang Song; Meng-Bei Xu; Xiao-Li Zhou; Dao-Pei Zhang; Shu-Ling Zhang; Guo-Qing Zheng
Journal:  Oxid Med Cell Longev       Date:  2017-03-13       Impact factor: 6.543

Review 4.  Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study.

Authors:  Md Jakaria; Md Ezazul Haque; Joonsoo Kim; Duk-Yeon Cho; In-Su Kim; Dong-Kug Choi
Journal:  Oncotarget       Date:  2018-09-11

Review 5.  Efficacy and Mechanism of Panax Ginseng in Experimental Stroke.

Authors:  Lei Liu; Gigi A Anderson; Tyler G Fernandez; Sylvain Doré
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

Review 6.  Protective effects of ginseng on neurological disorders.

Authors:  Wei-Yi Ong; Tahira Farooqui; Hwee-Ling Koh; Akhlaq A Farooqui; Eng-Ang Ling
Journal:  Front Aging Neurosci       Date:  2015-07-16       Impact factor: 5.750

7.  Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.

Authors:  Genevieve Z Steiner; Alan Bensoussan; Jianxun Liu; Mark I Hohenberg; Dennis H Chang
Journal:  Trials       Date:  2018-09-25       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.